David Novak

Stock Analyst at Raymond James

(0.60)

# 4,076

Out of 5,090 analysts

7

Total ratings

42.86%

Success rate

-16.31%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$26.69	+177.26%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$13.07	+1,965.80%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $26.69

Upside: +177.26%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $13.07

Upside: +1,965.80%